



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/SE/2024-25/57

August 26, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai 400 001

To,
Listing/ Compliance Department
**National Stock Exchange of India
Limited**
"Exchange Plaza", Plot No C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

BSE CODE: 524348

NSE CODE: AARTIDRUGS

Sub: Outcome of Board Meeting

Ref: Compliance of Regulation 30 and Regulation 42 of SEBI
(Listing Obligations and Disclosure Requirements)
Regulations, 2015.

Dear Sir/ Madam,

We wish to inform you that Board of Directors at its Meeting held on Monday, August 26, 2024, inter-alia, have approved the following:

Further to our intimation dated August 21, 2024 and in terms of Regulation 30 and 42(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 9(i) of Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended ("Buyback Regulations"), we wish to inform you that the Board of Directors at its meeting held today has approved:

The Buyback of up to 6,65,000 (*Six Lakhs Sixty Five Thousand*) fully paid-up equity shares of face value of Rs.10/- (Rupees Ten only) each of the Company ("Equity Shares") representing up to 0.72% of the total paid up Equity Shares of the Company at a price of Rs. 900/- (Rupees Nine hundred only) per Equity Share ("**Buyback Price**") payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (Rupees Fifty Nine Crores Eighty Five Lakhs Only) ("**Buyback Size**"), which is 5.16% and 4.74% of the fully paid- up equity share capital and free reserves, as per the audited standalone and consolidated balance sheet, respectively, of the Company as on March 31, 2024 (the last audited balance sheet available as on the date of Board meeting), on a proportionate basis through tender offer route ("Tender Offer") as prescribed under Buyback Regulations, to all the equity shareholders/ beneficiary owners who hold Equity Shares on the Record Date ("**Buyback**"). The Buyback period shall commence from the date of approval of buyback by the Board until the

last date on which the payment of consideration for the Equity Shares bought back by the Company is made (**“Buyback Period”**). The Buyback Size does not include any transaction costs viz. brokerage, applicable taxes inter alia including Buyback taxes, securities transaction tax, GST, stamp duty, expenses incurred or to be incurred for the Buyback like filing fees payable to Securities and Exchange Board of India (**“SEBI”**), any charges payable to the Stock Exchanges, advisors/legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc. (**“Transaction Cost”**).

The Board took note of intention of members of the promoter and promoter group including person in control of the Company to participate in the proposed Buyback.

The Board of Directors has determined the Record Date for the proposed Buyback as **September 5, 2024 (“Record Date”)**.

The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the Buyback Regulations.

The Company has formed a Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion deem necessary, expedient usual or proper in connection with the proposed Buyback.

Inga Ventures Private Limited has been appointed as the Manager to the proposed Buyback.

The details as per SEBI Circular Number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 along with the pre Buyback shareholding pattern of the Company are given as **Annexure “A”**.

The meeting of the Board of Directors commenced at 11 AM and concluded at 3:00 PM

This is for your information and records.

Thanking you,

Yours Faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. NO.:- F12932



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Annexure "A"

Details as per Annexure I of SEBI Circulated No. Circular Number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given below:

a) number of securities proposed for buyback;	6,65,000
b) number of securities proposed for buyback as a percentage of existing paid up capital	0.72%
c) Buyback price	Rs. 900 per Equity Shares
d) actual securities in number and percentage of existing paid up capital bought back	Will be intimated Post Buyback

e) Pre and Post shareholding pattern

Category of Shareholder	Pre Buy-back as on August 23, 2024		Post Buy-back*	
	Number of equity share held	% to the existing equity share capital	Number of equity share held	% to the existing equity share capital
A) Promoter and Promoter Group				
Individual	38332077	41.69		
Companies/Other Entities	12849776	13.98		
Total (A)	51181853	55.67		
B) Public Shareholder				
Institutions				
Mutual Funds	5628337	6.12		
Alternate Investment Funds	1455144	1.58		
Financial Institutions / Banks	16	0.00		
Insurance Companies	70691	0.08		
NBFCs registered with RBI	1095	0.00		
Foreign Portfolio Investors (Category I & II)	2668799	2.90		
Non-Institutions		0.00		
Directors and their relatives	5006308	5.45		
Relatives of promoters	323717	0.35		
Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'	67478	0.07		
IEPF	609625	0.66		
Individuals	22436159	24.40		
NRIs	696522	0.76		
Bodies Corporate	1076416	1.17		



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Trusts	25775	0.03		
Unclaimed or Suspense or Escrow Account	5066	0.01		
LLP	90911	0.10		
HUF	590001	0.64		
Clearing Members	1087	0.00		
Total (B)	40753147	44.33		
C) Non Promoter – Non Public	0.00	0.00		
TOTAL	91935000	100		

**Post Buyback shareholding pattern of the Company shall be ascertained subsequently*

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. NO.:- F12932